Ondansetron (OND) vs granisetron (GRA) in the control of chemotherapy induced acute emesis: A multicentric randomized trial

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 919-923

  Leonardi, V ^a   Iannitto, E ^a   Meli, M ^a   Palmeri, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

acute emesis; cancer chemotherapy; granisetron; ondansetron

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; GRANISETRON; METHOTREXATE; ONDANSETRON;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0029787643     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gralla RJ, Tyson LB, Kris MG, et al: The managment of chemotherapy-induced nausea and vomiting. Med Clin North Am 71: 289-301, 1987.
2. Miller LG: Metoclopramide-induced movement disorders: clinical findings with review of the literature. Arch Intern Med 149: 2486-2492, 1989.
3. Palmeri S, Gebbia V, Valenza R, et al: A randomized study on the antiemetic efficacy of levosulpiride versus metoclopramide as antiemetic therapy in cancer patients. J Exp Clin Chem 4: 114-117, 1991.
4. Blower PR: The role of specicfic 5HT3 receptor antagonism in the control of cyctostatic drug induced emesis. Eur J Cancer 26: 8-11, 1990.
5. Jones AL, Graham JL, Bosanquet N, et al: The budgetary impact of 5HT3 receptor antagonists in the managment of chemotherapy induced emesis. Eur J Cancer 29A: 1-6, 1992.
6. Andrews PLR, Bhandari P: The 5Hydroxytriptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 29A: 11-16, 1993.
7. Andrews PLR, Bhandari P, Davey PT, et al: Are all 5HT3 receptor antagonists the same? Eur J Cancer 28A: 2-6, 1992.
8. Priestman TJ: Clinical studies with ondansetron in the control of radiation induced emesis. Eur J Cancer Clin Oncol 25: 29-33, 1989.
9. Andrews PLR, Rapeport WG, Sanger GJ: Neuropharmacology of emesis induced by anticancer therapy. Trends Pharmacol Sci 9: 334-341, 1988.
10. Del Favero A, Roila F, Tonato M: Reducing chemotherapy induced nausea and vomiting. Drug Safety 9; 410-428, 1993.
11. Perez EA: Review of the clinical pharmacology and comparative efficacy of 5-Hydroxytryptamine-3 receptors antagonists for chemotherapy-induced emesis. J Clin Oncol 13: 1036-1043, 1995.
12. Roila F, Tonato M, Basurto C, et al: Ondansetron. Eur J Cancer 29A: 16-21, 1993.
13. Marty M: A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic induced emesis. Eur J Cancer 28A: 12-16, 1992.
14. Dilly S: Are granisetron and ondansetron equivalent in clinic? Eur J Cancer 28A: 32-35, 1992.
15. Noble A, Bremer K, Goedhais L, et al: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessmment of efficacy, safety and patient preference. Eur J Cancer 30A: 1083-1088, 1994.
16. Ruff P, Paska W, Goedhais L, et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced emesis: a multicentric, double blind, randomized, parallel group study. Oncology 51: 113-118, 1994.
17. Joss RA, Dott S: Clinical studies with granisetron, a new 5HT3 receptor antagonist for the treatment of cancer chemotherapy induced emesis. Eur J Cancer 29A: 22-29, 1993.
18. Marty M: A comparative study of the use of granisetron, a selective 5HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic induced emesis. Eur J Cancer 26: 28-32, 1990.
19. Herrstedt J, Sigsgaard T, Boesgaard M, et al: Ondansetron plus metopomimaziene compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076-1080, 1993.
20. Roila F, Tonato M, Cognetti F, et al: Prevention of cisplatin induced emesis: a double blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9: 675-678, 1991.
21. The Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1-5, 1995.
22. Tabona MV: An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy. Eur J Cancer 26: 37-41, 1990.
23. Cupissol DR, Serrou B, Caubel M, et al: The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high dose cisplatin-induced emesis. Eur J Cancer 26: 23-27, 1990.
24. Bresciani G, Bohm S, Oriana S: Control of nausea and vomiting by granisetron in ovarian cancer patients treated with different cisplatin based regimens. Tumori 80: 344-347, 1994.
25. Schmoll HJ: The role of ondansetron in the treatment of emesis induced by non cisplatin containing chemotherapy regimens. Eur J Cancer Clin Oncol 25: 35-39, 1989.
26. Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13: 1242-1248, 1995.
27. Darab K (on behalf of the Granisetron Study Group): Intravenous granisetron - establishing the optimal dose. Eur J Cancer 28A: 6-11, 1992.
28. Cunningham D, Pople A, Ford HT, et al: Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5HT3 receptor antagonist. Lancet i: 1461-1463, 1987.
29. Marty M, Droz JP, Pouillart P, et al: GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 23: 389-391, 1989.
30. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin emesis. Ann Oncol 6: 805-810, 1995.
31. Riviere A (on behalf of the Granisetron Study Group): Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69: 967-971, 1994.
32. Navari RM, Kaplan HG, Gralla RJ, et al: Efficacy and safety of granisetron, a selective 5-Hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 12: 2204-2210, 1994.
33. Beck TM, Hesketh PJ, Madajewicz S, et al: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single dose regimens in the prevention of cisplatin induced nausea and vomiting. J Clin Oncol 10: 1969-1975, 1992.
34. Ruff P, Paska W, Gohedals I, et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin induced acute emesis: A multicentre double-blind, randomized, parallel-group study. Oncology 51: 113-118, 1994.
35. Marty M: Ondansetron in the prophylaxis of acute cisplatin induced nausea and vomiting. Eur J Cancer Clin Oncol 25: 41-45, 1989.
36. Jantunen IT, Muhonen TT, Kataja VV, et al: 5HT3 receptors antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemo-therapy. A randomized study. Eur J Cancer 29A: 1669-1672, 1993.
37. Cupissol DR, Serrou B, Caubel M: The efficacy of granisetron as a prophylaxctic anti-emetic and intervention agent in high dose cisplatin-induced emesis. Eur J Cancer 26: 23-27, 1990.
38. The Italian Group for Antiemetic Research: Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1-5, 1995.
39. Jones AL, Hill AS, Soukop M, et al: Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483-487, 1991.
40. Hawthorn J, Cunningham D: Dexamethasone can potentiate the antiemetic action of a 5-HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61: 56-60, 1990.
41. Roila F, Bosxhetti E, Tonato M, et al: Predictive factors of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomised single blind study. Amer J Clin Oncol (CCT) 14: 238-242, 1991.
42. Kris MG, Gralla RJ, Tyoson LB, et al: Controlling delayed vomiting: double blind randomised trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7: 108-114, 1989.
43. Carmichael J: i.v. granisetron vs i.v. granisetron plus i.v. dexamethasone in the prophylaxis of emesis induced by cytoxic chemotherapy. Eur J Cancer 29A: 36, 1993.
44. Roila F, Tonato M, Basurio C, et al: Protection from nausea and vomiting in cisplatin treated patients: high dose metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Reasearch. J Clin Oncol 7: 1693-1700, 1989.
45. Martin MM, Diaz-Rubio E, Casado A, et al: Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 28: 430-432, 1992.
46. Magriet de Wet, Pharm B, Falkson G, et al: Repeated use of granisetron in patients receiving cytostatic agents. Cancer 71: 4043-4048, 1993.
47. Geert HB: Does granisetron remain effective over multiple cycles? Eur J Cancer 28: 17-21, 1992.